TÜBINGEN, GERMANY and AMSTERDAM, NETHERLANDS / ACCESSWIRE / June 8, 2022 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on ...
CureVac, bruised from its COVID-19 vaccine woes, has struck another deal to bolster its cancer vaccine development capabilities, buying Frame Cancer Therapeutics for its ability to identify unique and ...
FRAME study demonstrated a 42.3% ORR and 20.1 months median PFS for all patients with low-grade serous ovarian cancer (LGSOC), regardless of KRAS mutation; for patients with KRAS-mutated LGSOC, ORR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback